Lung Cancer pp 325-333 | Cite as

Detection of K-ras and p53 Mutations by “Mutant-Enriched” PCR-RFLP

  • Marcus Schuermann
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 75)


Early diagnosis of lung cancer is critical, as most cases are already inoperable at the time of diagnosis, and thus bear a grave prognosis. With increasing knowledge of the genetic aspects of lung cancer, the field has also experienced an increasing number of potential markers that might serve in the detection of changes in the lung epithelium that predispose to cancer (reviewed in refs. 1, 2, 3). Of these, oncogene mutations were among the first genetic biomarkers to be studied extensively, since they fulfill many criteria that link their de novo appearance to the process of field cancerization (4). Oncogene mutations of the ras- and p53-type are found in chronic smokers and patients with preneoplastic and neoplastic lesions but almost never in normal lung (4). In animal models carcinogens present in tobacco smoke have been shown to induce typical G-T transversions that lead to missense mutations (5). Moreover it has been shown that smoking leads to particular types of mutations, many of which are concentrated in particular hot spots, thus making it plausible that the same spectrum also arises in man on continuous exposure to tobacco carcinogens.


Oncogene Mutation Endonuclease Digestion Tobacco Carcinogen Bronchial Lavage Fluid Qiagen Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Sekido, Y., Fong, K. M., and Minna, J. D. (1998) Progress in understanding the molecular pathogenesis of human lung cancer. Biochim. Biophys. Acta 1378, F21–F59.PubMedGoogle Scholar
  2. 2.
    Salgia, R. and Skarin, A. T. (1998) Molecular abnormalities in lung cancer. J. Clin. Oncol. 16, 1207–1217.PubMedGoogle Scholar
  3. 3.
    Sozzi, G. and Carney, D. (1998) Molecular biology of lung cancer. Curr. Opin. Pulm. Med. 4, 207–212.PubMedCrossRefGoogle Scholar
  4. 4.
    Fong, K. M., Sekido, Y., and Minna J. D. (1999) Molecular pathogenesis of lung cancer. J. Thorac. Cardiovasc. Surg. 118, 1136–1152.PubMedCrossRefGoogle Scholar
  5. 5.
    Denissenko, M. F., Pao, A., Tang, M., and Pfeifer, G. P. (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274, 430–432.PubMedCrossRefGoogle Scholar
  6. 6.
    Rodenhuis, S. and Slebos, R. J. (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 52, 2665s–2669s.PubMedGoogle Scholar
  7. 7.
    Husgafvel-Pursiainen, K., Hackman, P., Ridanpaa, M., Anttila, S., Karjalainen, A., Partanen, T., et al. (1993) K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int. J. Cancer 53, 250–256.PubMedCrossRefGoogle Scholar
  8. 8.
    Li, S., Rosell, R., Urban, A., Font, A., Ariza, A., Armengol, P., et al. (1994) K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma. Lung Cancer 11, 19–27.PubMedCrossRefGoogle Scholar
  9. 9.
    Mao, L., Hruban, R. H., Boyle, J. O., Tockman, M., and Sidransky, D. (1994) Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 54, 1634–1637.PubMedGoogle Scholar
  10. 10.
    Mills, N. E., Fishman, C. L., Rom, W. N., Dubin, N., and Jacobson, D. R. (1995) Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 55, 1444–1447.PubMedGoogle Scholar
  11. 11.
    Mitsudomi, T., Viallet, J., Mulshine, J. L., Linnoila, R. I,. Minna, J. D., and Gazdar, A. F. (1991) Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6, 1353–1362.PubMedGoogle Scholar
  12. 12.
    Rodenhuis, S., Slebos, R. J., Boot, A. J., Evers, S. G., Mooi, W. J., Wagenaar, S. S., et al. (1988) Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 48, 5738–5741.PubMedGoogle Scholar
  13. 13.
    Rodenhuis, S. and Slebos, R. J. (1990) The ras oncogenes in human lung cancer. Am. Rev. Respir. Dis. 142, 27–30.CrossRefGoogle Scholar
  14. 14.
    Chiba, I., Takahashi, T., Nau, M. M., D’Amico, D., Curiel, D. T., Mitsudomi, T., et al. (1990) Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 5, 1603–1610.PubMedGoogle Scholar
  15. 15.
    Marchetti, A., Buttitta, F., Pellegrini, S., Campani, D., Diella, F., Cecchetti, D., et al. (1993) p53 mutations and histological type of invasive breast carcinoma. Cancer Res. 53, 4665–4669.PubMedGoogle Scholar
  16. 16.
    Takahashi, T., Suzuki, H., Hida, T., Sekido, Y., Ariyoshi, Y., and Ueda, R. (1991) The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6, 1775–1778.PubMedGoogle Scholar
  17. 17.
    Top, B., Mooi, W. J., Klaver, S. G., Boerrigter, L., Wisman, P., Elbers, H. R., et al. (1995) Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int. J. Cancer 64, 83–91.PubMedCrossRefGoogle Scholar
  18. 18.
    Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855–4878.PubMedGoogle Scholar
  19. 19.
    Sugio, K., Kishimoto, Y., Virmani, A. K., Hung, J. Y., and Gazdar A. F. (1994) K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res. 54, 5811–5815.PubMedGoogle Scholar
  20. 20.
    Fontanini, G., Vignati, S., Bigini, D., Merlo, G. R., Ribecchini, A., Angeletti, C. A., et al. (1994) Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J. Pathol. 174, 23–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Sozzi, G., Miozzo, M., Donghi, R., Pilotti, S., Cariani, C. T., Pastorino, U., et al. (1992) Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 52, 6079–6082.PubMedGoogle Scholar
  22. 22.
    Walker, C., Robertson, L. J., Myskow, M. W., Pendleton, N., and Dixon, G. R. (1994) p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br. J. Cancer 70, 297–303.PubMedCrossRefGoogle Scholar
  23. 23.
    Orita, M., Suzuki, T., and Hayashi, K. (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5, 874–879.PubMedCrossRefGoogle Scholar
  24. 24.
    Takahashi, N., Hiyama, K., Kodaira, M., and Satoh, C. (1990) An improved method for the detection of genetic variations in DNA with denaturing gradient gel electrophoresis. Mutat. Res. 234, 61–70.PubMedCrossRefGoogle Scholar
  25. 25.
    Anwar, K., Nakakuki, K., Shiraishi, T., Naiki, H., Yatani, R., and Inuzuka, M. (1992) Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res. 52, 5991–5996.PubMedGoogle Scholar
  26. 26.
    Yashiro, T., Fulton, N., Hara, H., Yasuda, K., Montag, A., Yashiro, N., et al. (1993) Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery 114, 758–763.PubMedGoogle Scholar
  27. 27.
    Lepage, V., Ivanova, R., Loste, M.N., Mallet, C., Douay, C., Naoumova, E., and Charron, D. (1995) Determination of DQB1 alleles using PCR amplification and allele-specific primers. Eur. J. Immunogenet. 22, 413–422.PubMedCrossRefGoogle Scholar
  28. 28.
    Ørum, H., Nielsen, P. E., Egholm, M., Berg, R. H., Buchardt, O., and Stanley, C. (1993) Single base pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res. 21, 5332–5336.PubMedCrossRefGoogle Scholar
  29. 29.
    Thiede, C., Bayerdorffer, E., Blasczyk, R., Wittig, B., and Neubauer, A. (1996) Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res. 24, 983–984.PubMedCrossRefGoogle Scholar
  30. 30.
    Behn, M., Thiede, C., Neubauer, A., Pankow, W., and Schuermann, M. (2000) Facilitated detection of oncogene mutations from exfoliated tissue material by a PNA-mediated ‘enriched PCR’ protocol. J. Pathol. 190, 69–75.PubMedCrossRefGoogle Scholar
  31. 31.
    Rhodes, C. H., Honsinger, C., Porter, D.M., and Sorenson, G. D. (1997) Analysis of the allele-specific PCR method for the detection of neoplastic disease. Diagn. Mol. Pathol. 6, 49–57.PubMedCrossRefGoogle Scholar
  32. 32.
    Kahn, S. M., Jiang, W., Culbertson, T. A., Weistein, I. B., Williams, G. M., Tomita, N., and Ronai, Z. (1991) Rapid and sensitive nonradioactive detection of mutant K-ras genes via ‘enriched’ PCR amplification. Oncogene 6, 1079–1083.PubMedGoogle Scholar
  33. 33.
    Levi, S., Urbano-Ispizua, A., Gill, R., Thomas, D. M., Gilbertson, J., Foster, C., and Marshall, C. J. (1991) Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res. 51, 3497–3502.PubMedGoogle Scholar
  34. 34.
    Jacobson, D. R. and Mills, N. E. (1994) A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia. Oncogene 9, 553–563.PubMedGoogle Scholar
  35. 35.
    Sugio, K., Kishimoto, Y., Virmani, A. K., Hung, J. Y., and Gazdar, A. F. (1994) K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res. 54, 5811–5815.PubMedGoogle Scholar
  36. 36.
    Mills, N. E., Fishman, C. L., Scholes, J., Anderson, S. E., Rom, W. N., and Jacobson, D. R. (1995) Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J. Natl. Cancer Inst. 87, 1056–1060.PubMedCrossRefGoogle Scholar
  37. 37.
    Behn, M., Qun, S., Pankow, W., Havemann, K., and Schuermann, M. (1998) Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based “enriched PCR” technique. Clin. Cancer Res. 4, 361–371.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2003

Authors and Affiliations

  • Marcus Schuermann
    • 1
  1. 1.Department of Hematology, Oncology and ImmunologyPhillipps-University of MarburgMarburgGermany

Personalised recommendations